| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Sept 2022 |  Dividend | ₹ 0.03 /share | 09 Sept 2022 | 9.18 | 9.18 |
| 26 Sept 2023 |  Annual General Meeting | NA | 26 Sept 2023 | 9.14 | 8.50 |
| 30 Sept 2024 | Annual General Meeting | NA | 30 Sept 2024 | 23.19 | 21.98 |
| 11 Nov 2024 |  Quarterly Result Announcement | NA | 11 Nov 2024 | 20.83 | 20.52 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 18.44 | 18.44 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 16.44 | 17.51 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 18.01 | 17.88 |
| 29 Sept 2025 | Annual General Meeting | NA | 29 Sept 2025 | 18.27 | 16.71 |
Syncom Formulations
16.63
+0.19
(1.16%)
Key Fundamentals
Market Cap
1,545.40 Cr
EPS
0.57
PE Ratio
27.28
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
23.87
52 Week Low
14.10
PB Ratio
4.57
Debt to Equity
0.12
Sector
Pharmaceuticals Actual
Company News
View All News
Syncom Formulations Announces Dual Leadership Resignations of CFO and Whole-time Director
Aug 18, 2025
Aug 18, 2025Syncom Formulations (India) Limited announced the resignation of two key executives effective August 8, 2025. Shri Ankit Kedarmal Bankda resigned from his position as Chief Financial Officer, while Smt. Rinki Ankit Banka stepped down from her roles as Director and Whole-time Director. The company filed the disclosure on August 18, 2025, explaining that the delay in submitting resignation letters was due to internal processing and final settlement formalities with the departing executives. The resignations affect the company's senior management structure and board composition.
Syncom Formulations Reports Strong Q1 Growth with Revenue Up 34% and Net Profit DoublingAug 08, 2025
Aug 08, 2025Syncom Formulations (India) delivered robust Q1 performance with revenue rising to 1.17 billion rupees from 872.6 million rupees year-over-year. Net profit more than doubled to 158 million rupees compared to 76.3 million rupees in the same period last year. EBITDA increased to 158 million rupees from 104.5 million rupees, while EBITDA margin improved to 13.52% from 11.98% year-over-year, indicating enhanced operational efficiency alongside revenue growth.
Syncom Formulations Board Approves Changes to Articles and Memorandum of AssociationAug 08, 2025
Syncom Formulations (India) Limited's Board of Directors approved alterations to the company's Articles of Association and Memorandum of Association at a meeting held on August 8, 2025. The changes include inserting new articles related to power purchase agreements, projects, sweat equity shares, and ESOP provisions. The Board also approved substituting the existing dividend waiver article and adding new business clauses for nutraceuticals, dietary supplements, wellness products, and real estate development activities. All proposed changes are subject to shareholder approval at the upcoming 37th Annual General Meeting scheduled for September 29, 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,706.40 | #1 4,05,655.60 | 39.40 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.65 | |
6,804.00 | 1,78,872.70 | 78.34 | 9,712.00 | 18.67 | 2,191 | 26.74 | 71.75 | |
1,511.50 | 1,21,268.10 | 22.47 | 28,409.50 | 7.12 | 5,291 | 3.71 | 41.32 | |
3,628.30 | 1,20,490.00 | 61.33 | 11,539.40 | 6.99 | 1,911 | 19.91 | 57.41 | |
1,196.00 | 99,953.30 | #1 17.40 | 33,741.20 | 16.73 | 5,725 | -0.38 | 33.50 | |
2,399.50 | 98,401.60 | 51.83 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.28 | |
981.05 | 98,052.50 | 20.95 | 23,511.00 | 18.55 | 4,615 | 2.60 | 43.10 | |
1,983.80 | 89,683.70 | 24.37 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 57.46 | |
1,158.60 | 66,147.50 | 20.02 | 32,345.60 | 9.43 | 3,484 | -10.24 | 66.97 | |
5,628.50 | 65,838.50 | 28.84 | 13,458.30 | 3.70 | 2,216 | 21.39 | 62.20 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
74.21 %
Net Income Growth
95.26 %
Cash Flow Change
493.29 %
ROE
64.39 %
ROCE
45.46 %
EBITDA Margin (Avg.)
-4.87 %
Corporate Action
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.06% | -188 | 0.00% | 0.00% |
Technical Indicators
RSI(14)
Neutral 42.73
ATR(14)
Volatile 0.44
STOCH(9,6)
Neutral 46.79
STOCH RSI(14)
Neutral 72.99
MACD(12,26)
Bullish 0.03
ADX(14)
Weak Trend 10.96
UO(9)
Bearish 37.49
ROC(12)
Uptrend And Accelerating 0.18
WillR(14)
Neutral -77.65
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
